StrongDecrease
Body weight
Tirzepatide → Body weight
Tirzepatide → Body weight
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Tirzepatide improves glycemic control in early-onset type 2 diabetes
Key finding
HbA1c decreased by -2.6% at week 40.
This study analyzed the effects of Tirzepatide on individuals with early-onset Type 2 diabetes, revealing significant improvements in various health markers.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Some Concerns bias
Last updated July 4, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Tirzepatide
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Primary outcome
HbA1c
Comparator
Comparator Interventions
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study analyzed the effects of Tirzepatide on individuals with early-onset Type 2 diabetes, revealing significant improvements in various health markers.
Clinical relevance
The findings highlight Tirzepatide's potential as a valuable treatment option for early-onset Type 2 diabetes, which is crucial for managing long-term health and preventing complications. Improved metabolic markers can lead to better overall health outcomes for patients.
Keep in mind
Effectiveness of Tirzepatide remains unclear due to limited evidence. Study results may not be generalizable to all populations. Sample size and duration may limit the robustness of findings.
Published in
Journal Reference
Publication details and source links for this paper.
Philip Z, Rodolfo JG, Melanie JD, et al. Post Hoc Analysis of Tirzepatide in Early-Onset Type 2 Diabetes: Baseline Characteristics and Treatment Effects. Diabetes Care. 2024;47(6):1056-1064. doi:10.2337/dc23-2356
Save this study and add notes to your research library.
Main Effects
HbA1c decreased by -2.6% at week 40.
Body weight decreased by -14 kg at week 40.
Waist circumference decreased by -10 cm at week 40.
Triglycerides decreased by -26% at week 40.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and Body weight, Diastolic blood pressure, Estimated glomerular filtration rate, and 7 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- Body weight
- Diastolic blood pressure
- Estimated glomerular filtration rate
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
10
Evidence pairs
10
Relationships
5
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
5
Related topics
10
Evidence pairs
516
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 10 evidence relationships
- Includes primary outcome data
- Linked to 5 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
Diastolic blood pressure
Tirzepatide → Diastolic blood pressure
Tirzepatide → Diastolic blood pressure
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
NoneNo Change
Estimated glomerular filtration rate
Tirzepatide → Estimated glomerular filtration rate
Tirzepatide → Estimated glomerular filtration rate
Evidence profile
NoneNo ChangeClinical Outcomes
Unlock full evidence details
NoneNo Change
Fasting Plasma Glucose (FPG)
Tirzepatide → Fasting Plasma Glucose (FPG)
Tirzepatide → Fasting Plasma Glucose (FPG)
Evidence profile
NoneNo ChangeGlycemic Control
Unlock full evidence details
StrongDecrease
HbA1c
Tirzepatide → HbA1c
Tirzepatide → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
NoneIncrease
HDL cholesterol
Tirzepatide → HDL cholesterol
Tirzepatide → HDL cholesterol
Evidence profile
NoneIncreaseMetabolic Health
Unlock full evidence details
NoneNo Change
Insulin resistance
Tirzepatide → Insulin resistance
Tirzepatide → Insulin resistance
Evidence profile
NoneNo ChangeMetabolic Health
Unlock full evidence details
StrongDecrease
Systolic blood pressure
Tirzepatide → Systolic blood pressure
Tirzepatide → Systolic blood pressure
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
StrongDecrease
Triglycerides
Tirzepatide → Triglycerides
Tirzepatide → Triglycerides
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
NoneDecrease
Waist circumference
Tirzepatide → Waist circumference
Tirzepatide → Waist circumference
Evidence profile
NoneDecreaseWeight & Anthropometrics
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- HbA1c levels decreased by -2.6%, indicating improved blood sugar control.
- Body weight reduction of -14 kg suggests significant weight loss benefits.
- Triglycerides decreased by -26%, reflecting improved lipid profiles.
Who this applies to
- Adults with early-onset Type 2 diabetes.
- Individuals seeking effective weight management strategies.
Keep in Mind
- Results may vary based on individual health conditions.
- Further research is needed to confirm long-term effects.
- The study's findings may not apply to older populations.
Between the Lines
- Effectiveness of Tirzepatide remains unclear due to limited evidence.
- Study results may not be generalizable to all populations.
- Sample size and duration may limit the robustness of findings.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
8 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
8 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
7 studies
outcome_hubMeasures Body Weight as a key outcome.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
1 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Tirzepatide and HbA1c
Intervention: TirzepatideOutcome: HbA1c
8 results
All studies on Tirzepatide and Body weight
Intervention: TirzepatideOutcome: Body weight
7 results
All studies on Tirzepatide
Intervention: Tirzepatide
8 results
All studies measuring HbA1c
Outcome: HbA1c
8 results
All studies measuring Body weight
Outcome: Body weight
7 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve HbA1c?
Moderate Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.9 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body weight?
Emerging Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 67.0 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 23 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve adipokine and angiogenic markers?
Emerging Evidence
GLP-1 Receptor Agonists appears to improve Adipokine and Angiogenic Markers.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Triglycerides
EvidenceScore™ Emerging | EvidenceScore™ 54.8 | strong positive | ConsensusScore™ Consistent | 1 study
- 2
HDL cholesterol
EvidenceScore™ Limited | EvidenceScore™ 33.0 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve insulin resistance?
Emerging Evidence
GLP-1 Receptor Agonists appears to improve Insulin Resistance.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Insulin resistance
EvidenceScore™ Limited | EvidenceScore™ 33.0 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies and existing graph evidence signals.
Limitations
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Mediterranean ketogenic eating matched VLCKD for weight loss over 3 monthsNewer diabetes drugs show stronger weight and blood sugar benefits in prediabetesGreenhabit app improves diabetes outcomes in adultsHRS-7535 improves glycemic control in adults with type 2 diabetesNatural products may improve glycemic control in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.